Your Article Summary
Reversal of refractory septic shock with drotrecogin alpha (activated)
Intensive Care Medicine, 07/02/09
Vieillard-Baron A et al. - The objective of this study was to investigate whether early administration of drotrecogin alpha (activated) (DrotAA) to this selected subgroup of septic patients at extremely high risk of death would significantly improve prognosis. DrotAA therapy was associated with unexpectedly high 28-day survival in patients with "refractory" septic shock.
Related Articles
Standardized order sets for the treatment of severe sepsis and septic shock
Expert Review of Anti-infective Therapy, 11/12/09
Relevance Score: 69%
An explorative study on quality of life and psychological and cognitive function in pediatric survivors of septic shock
Pediatric Critical Care, 11/10/09
Relevance Score: 69%
Corticosteroids for severe sepsis and septic shock
Intensivmedizin und Notfallmedizin, 11/06/09
Relevance Score: 69%
Is pituitary failure the real therapeutic target in septic shock
Medical Hypotheses, 11/04/09
Relevance Score: 69%
Beta-2-Adrenergic Receptor Gene Polymorphism is Associated with Mortality in Septic Shock
American Journal of Respiratory and Critical Care Medicine, 10/27/09
Relevance Score: 68%
Today in Critical Care...keeping you current
Receive free subspecialty "5-minute updates" via email
Fundamental and intensive care of acute pancreatitis
Journal of Hepato-Biliary-Pancreatic Surgery, 12/20/09
Use of gauze-based negative pressure wound therapy in a pediatric burn patient
Journal of Pediatric Surgery, 12/20/09
Modification of the Nuss procedure for pectus excavatum to prevent cardiac perforation
Journal of Pediatric Surgery, 12/20/09

See Latest Articles